Stallergenes Greer
Stallergenes Greer is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Stallergenes Greer.
Stallergenes Greer is a company.
Key people at Stallergenes Greer.
Key people at Stallergenes Greer.
Stallergenes Greer is a Swiss biopharmaceutical company specializing in the diagnosis and treatment of allergies through allergen immunotherapy (AIT), combining over 120 years of expertise from its predecessor companies. It develops and commercializes a broad portfolio of products including sublingual drops and tablets (e.g., Staloral, Oralair, Actair), subcutaneous injections (e.g., Alustal/Albey), oral immunotherapy for peanut allergies (Palforzia), allergen extracts, veterinary products, and testing supplies, serving patients with respiratory and food allergies worldwide via healthcare professionals.[1][2][4] Headquartered in Baar, Switzerland, with manufacturing in Europe, the US, and Canada, it employs 1,129 people across 21 countries (44 including distribution) and operates as a fully integrated global leader in AIT, owned by B-Flexion (formerly Waypoint Capital), a family-led investment firm focused on life sciences.[1][2]
The company addresses the growing global allergy burden by providing innovative, safe treatments that desensitize patients to allergens, improving quality of life through various administration modes.[2][4] Its growth stems from operational efficiencies, market share recovery, and investments in production capacity, as seen in 2019 financial improvements and expanded facilities.[6]
Stallergenes Greer traces its roots to two pioneering entities in allergy care. Greer Laboratories was founded in 1904 by R.T. Greer in the US as a collector of source materials like pollens, herbs, and roots, building expertise in allergen extracts over a century.[1][2] Stallergenes was established in 1962 in France by Institut Mérieux, focusing on innovation in AIT and desensitization therapies.[1][2]
The companies merged in 2015 to form Stallergenes Greer, uniting Greer's US manufacturing and extract prowess with Stallergenes' European R&D in sublingual and other AIT formats, creating a global powerhouse.[1][2][5] Previously, Stallergenes was owned by Wendel Group from 1993-2010, during which revenues grew 10x, establishing it as the world AIT leader before sale to the Bertarelli family's Ares Life Sciences (now under B-Flexion/Waypoint, full ownership by 2019).[3][6] This merger and ownership shift marked a pivotal moment, enabling delisting from the Paris stock exchange and a focus on long-term growth under Ernesto Bertarelli's chairmanship.[1][2][6]
Stallergenes Greer rides the rising tide of allergy prevalence—estimated at billions globally per EAACI data—driven by environmental, lifestyle, and urbanization factors, positioning AIT as a disease-modifying alternative to symptom management.[1][2] Its timing leverages biotech advances in immunotherapy, expanding from respiratory (e.g., grass/ragweed) to food allergies like peanuts, amid regulatory approvals and demand for non-invasive options like sublingual/oral formats.[2][6]
Market forces favor it through aging populations, climate-driven pollen surges, and post-merger scale, enabling competition with big pharma while influencing the ecosystem via manufacturing leadership, physician education, and supply reliability—critical in a fragmented allergy field.[1][4] As a private life sciences player under B-Flexion, it shapes biotech by demonstrating sustainable growth in niche therapeutics, inspiring similar consolidations.[2][3]
Stallergenes Greer is primed for expansion through R&D in new AIT platforms, capacity ramps, and geographic push, building on 2019's turnaround with regained market share and operational excellence.[6] Trends like personalized medicine, AI-driven diagnostics, and oral/food AIT approvals will propel it, especially as B-Flexion fuels life sciences investments.[2]
Its influence may evolve toward dominating global AIT supply amid allergy epidemics, potentially via acquisitions or novel therapies, solidifying its role as the century-spanning leader that merged legacies to treat millions—delivering on the promise of a healthier, allergy-resilient world.[1][2][4]
